Global Gabapentin Market 2026 supported by rising neurological disorder cases

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Gabapentin Market By The End Of 2030?

The gabapentin market size has experienced robust growth over recent years. Projections indicate it will expand from $3.01 billion in 2025 to reach $3.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical expansion is primarily due to factors such as epilepsy treatment adoption, neuropathic pain prevalence, generic drug availability, physician prescribing patterns, and the burden of chronic diseases.

The gabapentin market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $4.45 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this projected growth include an aging demographic, the rise of diabetic neuropathy, increased generic drug adoption, advancements in outpatient pain management, and the proliferation of telemedicine prescriptions. Key trends expected during this period encompass a heightened application in neuropathic pain management, a surge in demand for generic versions, the broadening of chronic pain treatment initiatives, the development of oral solid dosage forms, and a rise in prescriptions for various neurological conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Gabapentin Market?

The rising incidence of epilepsy is projected to fuel the expansion of the gabapentin market in the future. This neurological condition, epilepsy, manifests through recurrent seizures stemming from erratic electrical signals within the brain. The surge in epilepsy diagnoses primarily correlates with an expanding elderly demographic, given that aging heightens the susceptibility to neurological ailments leading to seizures. Gabapentin effectively manages epilepsy by moderating atypical neuronal activity in the brain and diminishing signals that instigate seizures. Its mechanism involves targeting calcium channels to aid in preventing the onset of seizures. As an illustration, data from February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicates that approximately 50 million individuals worldwide suffer from epilepsy. Significantly, nearly 80% of these individuals reside in low- and middle-income countries, and up to 70% have the potential to live without seizures through accurate diagnosis and appropriate treatment. Annually, an estimated 5 million new epilepsy cases are identified globally; this rate stands at approximately 49 per 100,000 in high-income nations, whereas in low- and middle-income countries, it can reach 139 per 100,000. Consequently, the expanding occurrence of epilepsy is stimulating the growth of the gabapentin market.

Which Segment Classifications Shape The Gabapentin Market?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

How Are Trends Impacting The Gabapentin Market?

Leading companies in the gabapentin market are concentrating on developing advanced formulations, such as bioequivalent tablets, to boost therapeutic effectiveness and broaden treatment options for neurological conditions. Bioequivalent tablets are generic medications that release an identical dose of the active ingredient into the bloodstream with the same speed and efficiency as the branded version, ensuring similar safety and therapeutic effects. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, which received approval from the United States Food & Drug Administration (USFDA) to expand the neurology portfolio in the US market. This innovative gabapentin features enhanced bioavailability, precise dosing, and patient-friendly administration, enabling more consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Gabapentin tablets USP, 600 mg, offer versatile therapeutic potential, providing effective management of a range of neurological conditions such as neuropathic pain and partial seizures through reliable dosing and proven clinical efficacy.

Which Companies Are Expanding Their Footprint In The Gabapentin Market?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

Read the full gabapentin market report here:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

Which Regions Are Projected To Dominate The Gabapentin Market In The Coming Years?

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gabapentin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

Browse Through More Reports Similar to the Global Gabapentin Market 2026, By The Business Research Company

Glycomic Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Antiglaucoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795